Inhibrx Delivers Differentiated Cancer Drug Data in Phase 2 Trial

Inhibrx's INBRX-106 Shows Differentiated Efficacy with Keytruda in Phase 2

Inhibrx Biosciences announced positive mid-stage results for its experimental drug INBRX-106 in combination with Merck & Co.'s Keytruda for a type of head and neck cancer. The Phase 2 trial demonstrated a 44% response rate for the combination therapy, significantly outperforming Keytruda alone, which showed a 21.4% response rate. The combination also yielded three complete responses, compared to none in the control group. Analysts suggest INBRX-106, an OX40 stimulator, could be a "first add-on mechanism" to enhance PD-1 immunotherapy. This news, alongside recent buyout rumors, has boosted Inhibrx's market value to nearly $2 billion.

• The Phase 2 study of INBRX-106 combined with Keytruda in head and neck cancer patients showed a 44% response rate, a substantial improvement over the 21.4% response rate seen with Keytruda monotherapy. Crucially, the combination arm achieved three complete responses, whereas no complete responses were observed in the control group, highlighting the potential for enhanced clinical benefit.
• INBRX-106 operates by stimulating the OX40 T cell receptor, offering a distinct "add-on mechanism" to existing PD-1 inhibition therapies like Keytruda. This approach is considered potentially differentiated, suggesting a new strategy to boost anti-tumor immune responses and overcome resistance mechanisms in cancer treatment.
• The positive mid-stage data, coupled with prior reports of potential acquisition interest from major pharmaceutical companies, has led to a significant increase in Inhibrx's market valuation, now approaching $2 billion. This reflects strong investor confidence and industry recognition of INBRX-106's potential to address unmet needs in oncology.

INBRX-106 + Keytruda: Differentiating Outcomes in Head and Neck Cancer

Clinical evidence from head and neck squamous cell carcinoma (HNSCC) demonstrates that several investigational approaches have shown superiority over standard-of-care treatments in specific patient populations. A landmark 2019 multinational phase 3 study comparing pembrolizumab with standard-of-care therapy in 495 patients with platinum-refractory recurrent or metastatic disease revealed significant clinical benefits. Pembrolizumab achieved a median overall survival of 8.4 months versus 6.9 months with standard-of-care treatments (methotrexate, docetaxel, or cetuximab), representing a 20% reduction in death risk (HR 0.80, p=0.0161). Equally important, pembrolizumab demonstrated a substantially improved safety profile, with grade 3 or worse treatment-related adverse events occurring in only 13% of patients compared to 36% in the standard-of-care group.

Meta-analyses of PD-1/PD-L1 inhibitors have consistently shown statistically significant survival benefits over standard therapies in the recurrent/metastatic setting, with a pooled odds ratio of 0.60 for death risk reduction (95% CI: 0.44-0.82, p=0.001). These immunotherapies have demonstrated particular efficacy in HPV-positive patients, who achieved higher objective response rates (18.8% versus 12.2%) and disease control rates (42.8% versus 34.4%) compared to HPV-negative patients. The most common treatment-related adverse event across PD-1/PD-L1 studies was fatigue (14.7%), with grade ≥3 events being relatively infrequent, highlighting the improved tolerability profile compared to conventional cytotoxic regimens.

Neoadjuvant investigational approaches have also shown promising activity compared to historical standard treatments. A 2025 study of paclitaxel-carboplatin neoadjuvant therapy achieved major pathologic response rates of 30.6%, with the highest activity observed in HPV-positive oropharyngeal cancer (44.7% MPR rate). This regimen demonstrated favorable safety with grade ≥3 adverse events occurring in 29.1% of patients, primarily neutropenia, while achieving 2-year overall survival of 89.2% and relapse-free survival of 75.5%. These outcomes compare favorably to historical controls and suggest potential for treatment de-escalation strategies in appropriately selected patient populations.

OX40 Stimulation: A Novel Mechanism for Head and Neck Cancer

Recent research has identified a diverse array of novel therapeutic targets for head and neck cancer, with immunotherapy advances leading the field. Emerging immunotherapeutics including bispecific antibodies, oncolytic viruses, and chimeric antigen receptor T cell therapies represent a promising frontier in locally advanced head and neck squamous cell carcinoma management. Two pivotal phase III trials (KEYNOTE-689 and NIVOPOSTOP) have demonstrated meaningful improvements in event-free and disease-free survival, supporting the integration of perioperative and adjuvant immunotherapy into curative strategies for resectable disease. Additionally, novel T cell activators such as STAR0602, a selective bifunctional T cell agonist targeting Vβ6 and Vβ10 T cell receptors fused to human interleukin-2, have shown clinical activity in anti-programmed death-ligand 1 resistant tumors.

Genomic-based drug discovery has revealed significant therapeutic opportunities through comprehensive molecular profiling. The GARD pipeline identified key genes associated with head and neck cancer across HPV-positive and HPV-negative subgroups, including PIK3CA, SOX2, TP53, EIF4G1, TLR7, CLDN1, PRKCI, and EPHA2, while protein-protein interaction network expansion identified additional targetable genes such as EGFR, ERBB2, and FGFRs. This genomic approach has yielded promising drug repurposing candidates, including compounds already in clinical trials (Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, Erdafitinib) and emerging candidates (Amuvatinib, XL765/Voxtalisib, Golotimod, Artenimol, Quercetin, Acetylsalicylic Acid). Epigenetic targets have also gained prominence, with histone deacetylase inhibitors showing a pooled cumulative proportion of favorable response of 0.65 among advanced head and neck cancer patients, with non-vorinostat inhibitors demonstrating superior efficacy (0.77 favorable response rate).

Innovative therapeutic approaches encompass both novel delivery systems and combination strategies targeting resistance mechanisms. STING agonists, particularly cyclic dinucleotides delivered through peptide hydrogel-liposome composite systems (K2-Lip(CDN)), have shown promising results with single-dose efficacy equivalent to six repeated doses in preclinical models. Boron neutron capture therapy has gained regulatory approval in Japan for recurrent head and neck cancer, offering cell-selective irradiation with next-generation boron delivery systems and theranostic approaches. The tumor microenvironment has emerged as a critical therapeutic target, with focus on tumor-associated macrophages, TGF-β-mediated exclusion pathways, and hypoxia-driven metabolic checkpoints including adenosine signaling, while precision medicine approaches increasingly emphasize biomarker-driven patient stratification and combination therapy strategies optimized for timing and sequencing according to tumor microenvironment dynamics.

Addressing Unmet Needs in Head and Neck Cancer Treatment

The head and neck cancer treatment landscape continues to face significant challenges despite advances in multimodal therapy approaches. Recent literature highlights persistent gaps in care, particularly for vulnerable patient populations and advanced disease settings. Key areas of focus include improving outcomes for elderly patients, addressing treatment resistance, and developing more effective therapeutic combinations.

• Elderly and frail patients represent a major underserved population, particularly those 70 years and older who are ineligible for surgery due to comorbidities and cannot tolerate standard cisplatin chemotherapy due to oto- and nephrotoxicity, with many only suitable for pembrolizumab monotherapy

• Recurrent and/or metastatic (R/M) disease remains a critical unmet need, developing in >50% of patients despite aggressive multimodal treatment, with response rates to checkpoint inhibitors remaining modest at 15-20% and long-term disease stabilizations being the exception

• Locally advanced unresectable disease poses ongoing challenges, with high recurrence rates after concomitant cisplatin-based chemoradiotherapy and inconsistent data on checkpoint inhibitor efficacy, underscoring the need for more precise patient selection and biomarker-driven approaches

• Treatment-resistant populations including patients with chemotherapeutic resistance and those with higher pyroptosis-related gene scores who have worse prognosis but may be more responsive to specific therapeutic combinations

• Biomarker development remains a critical gap, with the need for better predictive markers and targeted therapeutic agents to improve the persistently poor 5-year survival rate of 50%

• Advanced-stage oral cancers present particular challenges due to late-stage detection, limited treatment effectiveness, and severe side effects from current therapeutic options

INBRX-106: Validating OX40 as a Key PD-1 Enhancer

The recent positive mid-stage results for INBRX-106, an OX40 stimulator, in combination with Keytruda for head and neck cancer mark a significant moment for combination immunotherapy. Achieving a 44% response rate, more than double that of Keytruda alone, alongside complete responses, strongly validates the preclinical rationale for combining OX40 agonism with PD-1 blockade. Research has consistently shown that OX40 agonists can synergize with PD-1 inhibitors by enhancing T-cell activation, promoting tumor infiltration of cytotoxic and helper T cells, and fostering immune memory, thereby potentially overcoming resistance to existing checkpoint inhibitors.

This success positions INBRX-106 as a potential "first add-on mechanism" to PD-1 therapy, offering a new avenue to expand the utility of these foundational immunotherapies. For Inhibrx, this data significantly elevates its profile and market valuation, making it a compelling target for strategic partnerships or acquisition by larger players looking to strengthen their oncology portfolios.

However, the path forward is not without considerations:

• Translational Variability: While highly effective in head and neck cancer, the efficacy of OX40 agonist/PD-1 inhibitor combinations has shown more modest activity in other advanced solid tumors, such as gastrointestinal malignancies. This suggests that the robust response seen here may not uniformly translate across all cancer types, necessitating careful selection of future indications.

• Optimal Dosing and Sequencing: Preclinical studies highlight that the timing and sequence of administering OX40 agonists and PD-1 inhibitors can influence antitumor benefits. Further investigation into optimizing the regimen could potentially unlock even greater efficacy.

• Long-term Data: While early safety appears manageable, the long-term safety profile and durability of responses in a broader patient population will be critical to establish in larger Phase 3 trials.

Ultimately, these results provide strong evidence for the potential of OX40 agonism to enhance PD-1 blockade. The challenge now lies in navigating the complexities of clinical development to ensure broad applicability and sustained patient benefit, while also considering the strategic implications for market positioning and potential partnerships.